A Phase II Single-Institution Study of Neoadjuvant Stage III A/B Chemotherapy and Radiochemotherapy in Non-Small Cell Lung Cancer
|
|
- Agatha Stevens
- 6 years ago
- Views:
Transcription
1 A Phase II Single-Institution Study of Neoadjuvant Stage III A/B Chemotherapy and Radiochemotherapy in Non-Small Cell Lung Cancer Andreas Granetzny, MD, Eberhard Striehn, MD, Ulrich Bosse, MD, Wolfgang Wagner, MD, Olaf Koch, MD, Ulf Vogt, PhD, Peter Froeschle, MD, and Folker Klinke, MD Department of Thoracic Surgery, Ostercappeln, Institute of Pathology, Osnabrueck, Department of Radiation Therapy, Osnabrueck, Department of Hematology and Oncology, Osnabrueck, European Laboratory Association, Ibbenbueren, and Department of Thoracic Surgery, Duisburg, Germany GENERAL THORACIC Background. The relevance of a trimodal strategy in the treatment of lung cancer, consisting of neoadjuvant radiochemotherapy followed by surgery, is a subject of ongoing clinical trials. We tested whether improvement of long-term survival can be achieved for patients with stage III non-small cell lung cancer by this therapeutic approach. Methods. We performed a retrospective analysis of a single-institution phase II study. Of 33 patients enrolled in the protocol between 1992 and 1995, we reviewed the clinical outcomes of 26 patients with locally advanced non-small cell lung cancer (stage III A and III B ), which had been resected after combined chemotherapy and radiochemotherapy. Results. After neoadjuvant therapy, resection of the tumor was accomplished in all patients, and R0 resection was achieved in 92%. Histologic remission was found in 76% of these patients. Involvement of mediastinal lymph nodes was crucially important for the outcome. First, histologic clearance of the mediastinal compartment by neoadjuvant therapy resulted in a 27% 5-year survival rate. Second, patients with viable tumor in any of the mediastinal lymph nodes removed had a poor outcome (median survival 11.4 and 34.7 months in patients with and without viable tumor cells in the specimens, respectively; p 0.01). Conclusions. Histopathologic regression after neoadjuvant multimodal therapy including chemotherapy and radiotherapy was an important prognostic factor in a selected group of patients with locally advanced lung cancer. (Ann Thorac Surg 2003;75: ) 2003 by The Society of Thoracic Surgeons For a long time patients with bulky non-small cell lung cancer (NSCLC) or extensive nodal involvement (stage III) were considered ineligible for surgical intervention. Consequently, those patients were treated exclusively with radiation therapy as a definitive treatment. By introducing the concept of neoadjuvant therapy, chemotherapy and irradiation were adopted to shrink gross mediastinal tumor masses thus allowing complete resection of all of the initial manifestations of the tumor [1]. As emphasized by Green and Barkley [2], preoperative (or induction) therapy may have the advantage of being more effective before the emerging of clonal selection, thus preventing the occurrence of tumor cells not responding to chemotherapy. However, neoadjuvant therapy has been controversial. First, tumor progression can occur because of delayed surgery. Second, systemic toxicity might reduce the physical tolerance of the patients for subsequent resection; and third, intraoperative preparation may be affected by fibrosis, especially related to Accepted for publication Nov 1, Address reprint requests to Dr Granetzny, Department of Thoracic Surgery, Evangelisches Krankenhaus Duisburg-Nord, Fahrner Str. 133, Duisburg 47169, Germany; andreas.granetzny@ejk.de. radiation therapy [1]. Despite the well known disadvantages of multimodal therapy, surgery alone for treating stage III lung cancer can be justified only for highly selected patients [3]. As a result of these controversial issues, addressed by several investigators, ongoing trials are definitely required to define the most suitable sequence of multimodal therapy. Patients and Methods In a phase II study, between 1992 and 1995, 33 patients were treated by a protocol evaluating the feasibility of two courses of platinum-based chemotherapy, followed by radiochemotherapy and subsequent surgery. All patients were enrolled in the study according to the declaration of Helsinki. All patients underwent staging procedures, including radiologic imaging, bronchoscopy, and cervical mediastinoscopy. Patients with tumor involvement of the supraclavicular lymph nodes were excluded. Only patients with histologically proven NSCLC in stage III A und III B were eligible. Chemotherapy consisted of two courses of ifosfamide (1500 mg/m 2, days 1, 3, and 5), carboplatin (300 mg/m 2, 2003 by The Society of Thoracic Surgeons /03/$30.00 Published by Elsevier Science Inc PII S (02)
2 GENERAL THORACIC 1108 GRANETZNY ET AL Ann Thorac Surg MULTIMODAL TREATMENT OF STAGE III A/B NSCLC 2003;75: Table 1. Preoperative and Postoperative Formula of the Primary Tumor (n 26) Tumor Classification Preoperative (c) Postoperative (p) T0 0 8 T T T3 8 0 T4 7 1 c clinical; p pathohistological. Fig 1. Postoperative tumor stage (n 26). day 1), and etoposide (100 mg/m 2, days 1, 3, 5), followed by combined radiochemotherapy with a total dose of 45 Gy applied twice daily (with a single dose of 1.5 Gy each), carboplatin (100 mg/m 2, days 1, 8, and 15), and vindesine (3 mg, days 1, 8, and 15) within a 3-week interval. After radiologic restaging, revealing at least a no change status, patients underwent thoracotomy. If surgery was not feasible because of insufficient tumor remission (7 patients) or in case of residual tumor burden (R2 resection; n 2), subsequent irradiation up to a total dose of 60 Gy was completed by conventional fractionation. The nonresponders to neoadjuvant therapy were treated further off-study. The 26 patients operated on were evenly distributed to stages III A and III B. Twenty-five patients were male, with a median age of 57 years (range, 43 to 69 years), and the only female patient was 64 years old. At the beginning of therapy, the Karnowsky index of all patients exceeded 70%. Histologic examination showed squamous cell carcinoma (n 12), adenocarcinoma (n 7), large cell carcinoma (n 5), and other types of NSCLC (n 2). With regard to the Union Internationale Contre le Cancer staging system [4], after computed tomographic imaging, bronchoscopy, and mediastinoscopy, lung cancers were staged as follows: T2N2 (n 7), T2N3 (n 3), T3N2 (n 6), T3N3 (n 3), T4N2 (n 5), and T4N3 (n 2). All of the patients with T4 tumors had tumor invasion of the mediastinum. The following operations were performed: pneumectomy (n 8, six of these extended pneumectomies including one right-sided sleeve pneumectomy), bilobectomy (n 5, two extended), and lobectomy (n 12, seven sleeve resections, two cases with additional segmentectomy, and one case with partial replacement of the superior vena cava). In a patient with poor pulmonary function, only segmental resection with additional partial Table 2. Preoperative and Postoperative Nodal State (n 26) Lymph Node Classification Preoperative (c) Postoperative (p) N N1 0 5 N N3 7 0 c clinical; p pathohistological. removal of the chest wall was feasible. In 24 patients, R0 resections with radical mediastinal lymph node dissection were accomplished. Two patients were left with macroscopic residual tumor (R2 resection). Change of T stage after operation was shown for 24 patients (Table 1). The same observation was made concerning nodal status: 26 patients had N2 or N3 disease preoperatively and only 10 patients postoperatively (Table 2). According to our inclusion criteria, all patients enrolled in the study had been classified preoperatively as stage III, but only 9 patients were classified postoperatively as stage III A (n 8) or III B (n 1), as shown in Figure 1. Complete histopathologic remission was observed in 8 patients (30.7%, tumor), 10 patients (38.5%, lymph nodes), and 6 patients (23%, tumor and lymph nodes). Classification of remission rates was performed according to a modified Salzer-Kuntschik technique, originally developed for the evaluation of neoadjuvant chemotherapy in osteogenic sarcoma [5]. Grades 1 to 3 were classified as responders, whereas grades 4 to 6 were considered nonresponders to neoadjuvant therapy. Seventy-six percent (n 25) were responders and 24% (n 8) were classified as nonresponders (Table 3). Using the Kaplan-Meier method [6] survival was estimated from date of operation. Comparison of survival of different discriminative factors was tested for significance by the log rank test [7]. Results The median survival time for all patients has been 15.4 months (range, 2.8 to months). The difference in survival of patients who had an operation compared with Table 3. Histopathological Remission Rate According to the Salzer-Kuntschik Classification [5] Grade Responder I 10 II 7 76% III 8 Nonresponder IV VI 1 Tumor progress, no surgery 7 n 24% Grade I no vital tumor cells; Grade II single tumor cells; Grade III less than 10 % vital tumor tissue; Grade IV 10% 50% vital tumor tissue; Grade V more than 50% vital tumor tissue; Grade VI no effect of chemotherapy. } }
3 Ann Thorac Surg GRANETZNY ET AL 2003;75: MULTIMODAL TREATMENT OF STAGE III A/B NSCLC 1109 GENERAL THORACIC Fig 2. Cumulative survival in clinical stage III A (solid line) and stage III B (dotted line). The difference between the two curves is not significant. those treated off-protocol with only chemotherapy and radiation was statistically significant (19.5 versus 8.4 months, respectively, p ). Of the 26 patients who had an operation after combined radiochemotherapy, 18 (69%) survived for 1 year, 11 (42%) for 2 years, and 7 (27%) for 5 years. The median survival time for patients with stage III A status was 24 months and for patients with stage III B status, 13 months. The difference between the two groups was not statistically significant (p 0.675) (Fig 2). In a multivariate analysis, we searched for factors that might affect survival of the patients who were operated on. No influence on survival was documented for age, histology, grading, or T status. The most important effect on survival was the extent of histopathologic regression of the mediastinal lymph nodes (p ). If the patient s mediastinal lymph nodes were free of tumor cells, these patients had a significantly better prognosis than the ones with remnant tumor (Fig 3). The remission rate of lymph nodes was scored according to the method of Salzer-Kuntschik and coworkers [5]. The median survival time for patients with grade I status postoperatively was 34.7 months (n 10). In contrast, patients with grade II status had a median survival time of 12.6 months (n 7). Patients with a grade III lymph node status (remaining viable tumor cells less than 10%) had a median survival time of 8.9 months (n 8). Only 1 patient was confirmed to have a grade IV status at the time of operation after combined trimodal treatment. At the time of investigation (accrual for protocol until May 1, 2001) with a median follow-up time of 32 months, 7 patients (27%) are still alive without any evidence of tumor relapse or metastatic disease, and all of them have an excellent performance status. For this subgroup, the Fig 3. Long-term survival and remission rates in mediastinal lymph nodes. The difference between the groups with and without malignant cells in the mediastinal lymph nodes was significant (log rank p ). Solid line no malignant cells in mediastinal lymph node (n 10); evenly dotted line malignant cells in mediastinal lymph node (n 16); and unevenly dotted line no operation (n 7). median survival time currently exceeds 90 months. Seven patients (27%) had a long-term survival of more than 60 months (stage III A n 4; stage III B n 3), and four patients (15%) had a long-term survival of more than 90 months. In 5 of those 7 patients there were no viable tumor cells in the mediastinal lymph nodes after dissection (grade I status). In 1 patient some residual tumor cells (grade II) were found, and in another patient less than 10% of tumor cells could be traced in the lymph nodes (grade III). Severe adverse effects during chemoradiotherapy included leucopenia in 4 patients (World Health Organization [WHO] grade III/IV) and thrombopenia in 3 patients (WHO grade III/IV). After radiotherapy, 3 patients had esophagitis (WHO grade III/IV), and 4 patients had clinical signs of pneumonitis. One patient died of pneumonitis resulting from irradiation on the 50th postoperative day. Another patient died on postoperative day 105 because of bronchial stump insufficiency, presumably as a result of postoperative irradiation. Two patients died of cardiac failure on day 32 and day 60. Neoadjuvant multimodal therapy affects the performance status of the patient and induces local inflammatory reactions of the tumor bed and surrounding tissues. Therefore surgical therapy of these patients remains a challenge.
4 GENERAL THORACIC 1110 GRANETZNY ET AL Ann Thorac Surg MULTIMODAL TREATMENT OF STAGE III A/B NSCLC 2003;75: Comment For most patients with advanced lung cancer the advent of multidisciplinary approaches has dramatically changed the treatment of these tumors. Long-term survival is conceivable for certain patients, who already have been identified and whose characteristics still have to be determined by multidisciplinary studies. At present, the most reliable predictor remains the TNM tumor stage [8]. Recently, a further prognostic factor, response to therapy, for combined modality treatment regimens has been evaluated [1]. The standard induction regimen, ie, the chemotherapy protocol and the schedule and type of fractionation of radiotherapy, have not been agreed upon yet. Several ongoing studies were performed with the aim of improving survival in locally advanced NSCLC [9 12]. Published data from clinical trials are difficult to analyze because of the heterogeneity of the different inclusion criteria of these multicenter studies. Several studies have been restricted either to stage III A or III B. The Southwest Oncology Group trial included both stage III A and III B [12], whereas the Rush-Presbyterian trial included patients with T3N0 tumors (now II B ) [13], and at the Dana Faber Institute patients with T3N0 tumors as well as N2 disease were enrolled [14]. Threeyear survival rates between 18% and 33% have been reported, and long-term survivors (more than 5 years) hardly exist [1]. Histopathologic Examination The two-dimensional evaluation of histopathologic remission according to Salzer-Kuntschik and colleagues has been modified (by U.B.) to a three-dimensional method. The remission rate was 76% (complete remission of tumor and lymph nodes in 23%). Histopathologic absence of tumor was also observed in 22% of resected specimens in the Rush-Presbyterian trial. The authors emphasized that this result did not correlate with the disappearance of disease shown by radiologic imaging [15]. That finding is in accordance with our own experience [16]. Consequently all patients without progression of disease on radiologic imaging should be considered for operation. Thus, staging thoracotomy is recommended to decide on tumor resectability. The strongest prognostic factor in our study is the histopathologic remission rate of mediastinal nodes. This finding is in accordance with the data of one of the largest phase II trials, the Southwest Oncology Group 8805 study, published by Albain and associates [9] and Rusch and colleagues [12]. They applied induction chemotherapy and concurrent irradiation therapy to 154 patients with stage III A and III B disease. Patients with a histologically complete response by the lymph nodes had a median survival of 30 months, compared with 10 months for those with persistent lymph node disease (p ). According to Albain and coworkers [9] the strongest predictor of long-term survival was the absence of tumor involvement in mediastinal nodes at the time of operation, with a 3-year survival rate of 44% versus 18% in those who had persistent nodal disease (p ). In our study, 26 patients were operated on, and complete resection was achieved in 24 (92%) patients. Twenty-seven percent of all resections were performed as parenchymal sparing sleeve resections because of poor pulmonary function. As in our institution, the rate of this type of operation does not exceed more than 10% even in large centers. It is well known to thoracic surgeons that radiation-induced vascular obliterations are likely to cause delayed healing of the bronchial anastomosis. For this reason, we performed histologic examinations of the small vessels at the resection margins of the bronchi. We found blood vessels without any structural damage (data not shown). Obliteration of blood vessels has been observed only in the bed of the primary tumor. Consequently it is mandatory to perform the bronchial anastomosis away from the region of the primary tumor. The 5-year survival rate reported in our study (27%) exceeds survival rates for stage III A and III B reported in the literature. This discrepancy might be related to our selection of patients for surgical resection, because only patients with at least no progression of disease were operated on. Resectability and Long-Term The rates of complete resection have varied considerably between 23% [17] and 88% [14]. In the second trial at the Dana Faber Institute, only 44% of the tumors could be resected completely [18]. The high resectability rate in the first trial at the Dana Faber Institute [14] can be explained by the fact that patients with T3N0 tumors (actually stage II B ) were included, as well as patients with N2 mediastinal metastases; stage III B patients were excluded from the study. The resectability rate in our study (100%) with 92% R0 resections could explain the excellent outcome of our patients. The favorable effect of complete resection on median survival rate was also found by Elias and coworkers (second trial at the Dana Faber Institute [18]). The median survival time was 17.9 months overall and 33.5 months when the tumor could be removed completely. It is evident that the unsatisfying data (median survival 11 months, 2-year survival rate 8%) of one of the first trials of combined chemoradiation therapy [19] are a consequence of the low resectability rate. This should also be considered in the Lung Cancer Study Group (LCSG) trial, which had a median survival of 13 months after thoracotomy with only 34% complete resections [20]. Only a few studies with preoperative radiochemotherapy reported long-term results of 5 years or more (Table 4). The 5-year survival rates were between 13% and 37%. In our study, 7 of the 26 patients who were operated on were alive after 5 years (27%); among them are 4 patients in stage III A and 3 patients in stage III B. Three patients (15%) are alive at more than 90 months postoperatively.
5 Ann Thorac Surg GRANETZNY ET AL 2003;75: MULTIMODAL TREATMENT OF STAGE III A/B NSCLC Table 4. Long-Term Rates for Neoadjuvant Chemoradiation Therapy for Non-Small Cell Lung Cancer Reference Patients (n) Median (mo) 5-Year (%) 6-Year (%) Year (%) GENERAL THORACIC Spain [17] Skarin and colleagues [14] Taylor [13] Favaretto [11] Choi and colleagues [21] Present study Complications Aggressive trimodal treatment is associated with significant morbidity in our study. Many patients had severe side effects during radiochemotherapy (4 patients with leucopenia WHO grade III/IV, 3 patients with thrombopenia WHO grade III/IV, 3 patients with esophagitis, and 4 patients with pneumonitis). In the late postoperative period, 1 patient died of cardiac failure on the 32nd postoperative day, and 1 patient succumbed to a bronchial stump leak and pneumonitis. At autopsy of the patient with cardiac failure, complete occlusion of the coronary arteries was found. Based on this experience, we decided to exclude patients with severe peripheral arteriosclerosis from recruitment in the subsequent phase III study. The Southwest Oncology Group investigators [9, 12] noted substantial toxicity as well: 13% of patients had grade IV acute toxicity, and there were two treatmentrelated deaths (1.6%) during the induction therapy period. During the postoperative period 11 (8.4%) additional deaths occurred. An overall treatment-related mortality rate of 15% was found in the neoadjuvant study by Burkes and associates from Toronto [10]. The results of this study and our experience with neoadjuvant therapy in NSCLC have shown that patients with stage III A and III B NSCLC enjoy long-term survival with tolerable therapy-induced morbidity and mortality. Among all known prognostic factors the histopathologic regression of mediastinal lymph nodes has had the most effect on survival. Additionally, the experience of this study showed that 1. Grade of remission of the primary tumor cannot be analyzed exclusively by roentgenogram or computed assisted tomography. 2. Staging thoracotomy is recommended in most cases to evaluate the chance for radical resection. 3. The primary tumor bed must be radically resected, irrespective of histologic evidence of tumor tissue. 4. Resection of the primary tumor bed must be performed beyond the margins of fibrotic tissue resulting from radiochemotherapy, and sleeve resections are feasible without a significant complication rate. References 1. Singhal S, Kaiser LR. Multimodality therapy for non-small cell lung cancer. In Shields TW, Locicero J, Ponn RB, eds. General thoracic surgery. Philadelphia: Lippincott, 2000: Green MR, Barkley JE. Intensity of neoadjuvant therapy in resectable non-small cell lung cancer. Lung Cancer 1997; 17(Suppl 1):S Rocmans P, Capello M, de Franquen P. Exclusive surgery for stage III disease: is it still ethical?. In: van Houtte P, Klastersky J, Rocmans P, eds. Progress and perspectives in the treatment of lung cancer. Berlin: Springer, 1999: Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111: Salzer-Kuntschik M, Brand G, Delling G. Bestimmung des morphologischen Regressionsgrades nach Chemotherapie bei malignen Knochentumoren. Pathologe 1983;4: Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J Stat Soc 1972;135: LoCicero J III, Ponn RB, Daly BDT. Surgical treatment of non-small cell lung cancer. In: Shields TW, LoCicero J, Ponn RB, eds. General thoracic surgery. Philadelphia: Lippincott, 2000: Albain KS, Rusch VW, Crowley JJ. Concurrent cisplatin/ etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung cancer: mature results of Southwest Oncology Group phase II study J Clin Oncol 1995;13(8): Burkes RL, Ginsberg RJ, Shepherd FA. Induction chemotherapy with mitomycin, vindesine and cisplatin for stage III unresectable non-small cell lung cancer. Results of the Toronto Phase II Trial. J Clin Oncol 1992;10: Favaretto A. Preoperative chemoradiotherapy in non-small cell lung cancer stage III patients. Feasibility, toxicity and long-term results of a phase II study. Eur J Cancer 1996;32A: Rusch VW, Albain KS, Crowley JJ, et al. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. J Thorac Cardiovasc Surg 1993;105: Tailor SG. Simultaneous cisplatin fluorouracil infusion and radiation followed by surgical resection in regionally localized stage III, non-small cell lung cancer. Ann Thorac Surg 1987;43: Skarin A, Jochelson M, Sheldon T, et al. Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: long-term follow-up in 41 patients. J Surg Oncol 1989;40(4): Bonomi P. Radiation and simultaneous cisplatin in nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1993;27:
6 GENERAL THORACIC 1112 GRANETZNY ET AL Ann Thorac Surg MULTIMODAL TREATMENT OF STAGE III A/B NSCLC 2003;75: Riesenbeck D, Rübe C, Thomas M, et al. Korrelation von Bildgebung, Resektabilität und histologischem Therapieansprechen nach präoperativer, kombinierter Radiochemotherapie beim NSCLC. Strahlenther Onkol 1997;1: Spain RC. Neoadjuvant mitomycin C, cisplatin, and infusion vinblastine in locally and regionally advanced non-small cell lung cancer: problems and progress from the perspective of long-term follow-up. Semin Oncol 1998;15(Suppl 4): Elias AD, Skarin AT, Gonin R, et al. Neoadjuvant treatment of stage IIIA non-small cell lung cancer. Long-term results. Am J Clin Oncol 1994;17: Eagan RT, Ruud C, Lee RE. Pilot study of induction therapy with cyclophosphamide, doxorubicin and cisplatin (CAP) and chest irradiation prior to thoracotomy in initially inoperable stage III M0 non-small cell lung cancer. Cancer Treat Res 1987;71: Weiden PL, Piantadosi S. Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small cell lung cancer. A phase II study of the LCSG. Chest 1994;106(Suppl): Choi NC, Carey RW, Daly W, et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol 1997;15(2): Notice From the American Board of Thoracic Surgery Regarding Trainees and Candidates for Certification Who Are Called to Military Service Related to the War on Terrorism The Board appreciates the concern of those who have received emergency calls to military service. They may be assured that the Board will exercise the same sympathetic consideration as was given to candidates in recognition of their special contributions to their country during the Vietnam conflict and the Persian Gulf conflict with regard to applications, examinations, and interruption of training. If you have any questions about how this might affect you, please call the Board office at (847) Peter C. Pairolero, MD Chairman The American Board of Thoracic Surgery 2003 by The Society of Thoracic Surgeons Ann Thorac Surg 2003;75: /03/$30.00 Published by Elsevier Science Inc
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationLung cancer is the leading cause of cancer-related
Advanced Non-Small Cell Lung Cancer: Induction Chemotherapy and Chemoradiation Before Operation Arnold Cyjon, MD, Moshe Nili, MD, Gershon Fink, MD, Mordechai R. Kramer, MD, Eyal Fenig, MD, Judith Sandbank,
More informationInduction chemotherapy followed by surgical resection
Surgical Resection for Residual N 2 Disease After Induction Chemotherapy Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Matthew A. Levin, BS, David E. Becker, MA, Roger Keresztes, MD, and Nasser
More informationShort-Course Induction Chemoradiotherapy With Paclitaxel for Stage III Non-Small-Cell Lung Cancer
Short-Course Induction Chemoradiotherapy With Paclitaxel for Stage III Non-Small-Cell Lung Cancer Thomas W. Rice, MD, David J. Adelstein, MD, Jay P. Ciezki, MD, Mark E. Becker, MD, Lisa A. Rybicki, MS,
More informationPneumonectomy After Induction Rx: Is it Safe?
Pneumonectomy After Induction Rx: Is it Safe? David J. Sugarbaker, M.D. Director, Chief, Division of Thoracic Surgery The Olga Keith Weiss Chair of Surgery of Medicine at, Pneumonectomy after induction
More informationSmall cell lung cancer (SCLC), which represents 20%
ORIGINAL ARTICLES: GENERAL THORACIC Surgical Results for Small Cell Lung Cancer Based on the New TNM Staging System Masayoshi Inoue, MD, Shinichiro Miyoshi, MD, Tsutomu Yasumitsu, MD, Takashi Mori, MD,
More informationComplete surgical excision remains the greatest potential
ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,
More informationTreatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer
Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationAlthough ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis
Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,
More informationCase presentation. Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium
Case presentation Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium Perspectives in Lung Cancer Brussels 6-7 march 2009 LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery
More informationLung cancer pleural invasion was recognized as a poor prognostic
Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationThe roles of adjuvant chemotherapy and thoracic irradiation
Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationIn 1989, Deslauriers et al. 1 described intrapulmonary metastasis
ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,
More informationHISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018
30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective
More informationLA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II
AUSL BA/4 Ospedale S. Paolo Bari U.O. Complessa di Chirurgia Toracica LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II stadio L opinione del chirurgo Francesco
More informationLung cancer Surgery. 17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY March, 2017 Berlin, Germany
17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY 24-29 March, 2017 Berlin, Germany Lung cancer Surgery Sven Hillinger MD, Thoracic Surgery, University Hospital Zurich Case 1 59 y, female, 40 py, incidental
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationORIGINAL ARTICLES. Neoadjuvant Therapy: A Novel and Effective Treatment for Stage IIIb Non-Small Cell Lung Cancer
ORIGINAL ARTICLES _ Neoadjuvant Therapy: A Novel and Effective Treatment for Stage IIIb Non-Small Cell Lung Cancer Valerie W. Rusch, MO, Kathy S. Albain, MO, John J. Crowley, PhD, Thomas W. Rice, MO, Vassyl
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationAccording to the current International Union
Treatment of Stage II Non-small Cell Lung Cancer* Walter J. Scott, MD, FCCP; John Howington, MD, FCCP; and Benjamin Movsas, MD Based on clinical assessment alone, patients with stage II non-small cell
More informationJ. MAXWELL CHAMBERLAIN MEMORIAL PAPER. Preoperative Chemotherapy for Stage IIIa (N2) Lung Cancer: The Sloan-Kettering Experience With 136 Patients
J. MAXWELL CHAMBERLAIN MEMORIAL PAPER Preoperative Chemotherapy for Stage IIIa (N2) Lung Cancer: The Sloan-Kettering Experience With 136 Patients Nael Martini, MD, Mark G. Kris, MD, Betty J. Flehinger,
More informationVATS after induction therapy: Effective and Beneficial Tips on Strategy
VATS after induction therapy: Effective and Beneficial Tips on Strategy AATS Focus on Thoracic Surgery Mastering Surgical Innovation Las Vegas Nevada Oct. 27-28 2017 Scott J. Swanson, M.D. Professor of
More informationEVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI
EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI Overview Introduction Diagnostic work up Treatment Group 1 Group 2 Group 3 Stage III lung cancer Historically was defined as locoregionally advanced
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationMEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER
MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo
More informationand Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationNeoadjuvant Chemoradiation for Clinically Advanced Non-Small Cell Lung Cancer: An Analysis of 233 Patients
Neoadjuvant Chemoradiation for Clinically Advanced Non-Small Cell Lung Cancer: An Analysis of 233 Patients Anthony W. Kim, MD, Michael J. Liptay, MD, Philip Bonomi, MD, William H. Warren, MD, Sanjib Basu,
More informationLymph node dissection for lung cancer is both an old
LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko
More informationControversies in management of squamous esophageal cancer
2015.06.12 12.47.48 Page 4(1) IS-1 Controversies in management of squamous esophageal cancer C S Pramesh Thoracic Surgery, Department of Surgical Oncology, Tata Memorial Centre, India In Asia, squamous
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationThe surgeon: new surgical aproaches
The surgeon: new surgical aproaches Paul Van Schil, MD Department of Thoracic and Vascular Surgery Antwerp University, Belgium no disclosures, no conflict of interest Malignant pleural mesothelioma: clinical,
More informationInduction Chemoradiation Therapy with Cisplatin plus Irinotecan Followed by Surgical Resection for Superior Sulcus Tumor
Original Article Induction Chemoradiation Therapy with Cisplatin plus Irinotecan Followed by Surgical Resection for Superior Sulcus Tumor Katsuhiko Shimizu, 1 Masao Nakata, 1 Ai Maeda, 1 Takuro Yukawa,
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationOverall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer
Original Article Overall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer Faisal A. Siddiqui 1, Katelyn M. Atkins 2, Brian S. Diggs 3, Charles R. Thomas Jr 1,
More informationOutcome of nonsurgical treatment for locally advanced thymic tumors
Original Article Outcome of nonsurgical treatment for locally advanced thymic tumors Chang-Lu Wang 1, Lan-Ting Gao 1, Chang-Xing Lv 1, Lei Zhu 2, Wen-Tao Fang 3 1 Department of Radiation Oncology, 2 Department
More informationCarcinoma of the Lung
THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 1 I - NUMBER 3 0 MARCH 1971 Carcinoma of the Lung M. L. Dillon, M.D., and
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationShort- and Long-Term Outcomes after Pneumonectomy for Primary Lung Cancer
Original Article Short- and Long-Term Outcomes after Pneumonectomy for Primary Lung Cancer Takeshi Kawaguchi, MD, Takashi Tojo, MD, Keiji Kushibe, MD, Michitaka Kimura, MD, Yoko Nagata, MD, and Shigeki
More informationThe tumor, node, metastasis (TNM) staging system of lung
ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,
More informationRTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
More informationSleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib
Case Report Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib Ichiro Sakanoue 1, Hiroshi Hamakawa 1, Reiko Kaji 2, Yukihiro Imai 3, Nobuyuki Katakami 2, Yutaka Takahashi 1 1 Department
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationDisclosures. Preoperative Treatment: Chemotherapy or ChemoRT? Adjuvant chemotherapy helps. so what about chemo first?
Disclosures Preoperative Treatment: Chemotherapy or ChemoRT? Advisory boards Genentech (travel only), Pfizer Salary support for clinical trials Celgene, Merck, Merrimack Matthew Gubens, MD, MS Assistant
More informationAlthough esophagectomy remains the standard of care for esophageal
Keresztes et al General Thoracic Surgery Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: Results of a phase II trial R. S. Keresztes, MD J. L. Port, MD M. W. Pasmantier,
More informationCHAPTER 5 TUMOR SIZE DOES NOT PREDICT PATHOLOGICAL COMPLETE RESPONSE RATES AFTER PRE-OPERATIVE CHEMORADIOTHERAPY FOR NON-SMALL CELL LUNG CANCER
TUMOR SIZE DOES NOT PREDICT PATHOLOGICAL COMPLETE RESPONSE RATES AFTER PRE-OPERATIVE CHEMORADIOTHERAPY FOR NON-SMALL CELL LUNG CANCER Cornelis G. Vos Max R. Dahele Chris Dickhoff Suresh Senan Erik Thunnissen
More informationImpact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer
Impact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer Jakob R. Izbicki, MD, Bernward Passlick, MD, Ortrud Karg, MD, Christian Bloechle, MD, Klaus Pantel, MD, Wolfram
More informationResection of retroperitoneal residual mass after chemotherapy in patients with nonseminomatous testicular cancer
Turkish Journal of Cancer Vol.31/ No. 2/2001 Resection of retroperitoneal residual mass after chemotherapy in patients with nonseminomatous testicular cancer AHMET ÖZET 1, ALİ AYDIN YAVUZ 1, MURAT BEYZADEOĞLU
More informationLung Cancer Clinical Guidelines: Surgery
Lung Cancer Clinical Guidelines: Surgery 1 Scope of guidelines All Trusts within Manchester Cancer are expected to follow this guideline. This guideline is relevant to: Adults (18 years and older) with
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationPostoperative Adjuvant Therapy for Stage II Non Small-Cell Lung Cancer
Postoperative Adjuvant Therapy for Stage II Non Small-Cell Lung Cancer Jong Ho Park, MD, Young Mog Shim, MD, Hee Jong Baek, MD, Mi-Sook Kim, MD, Du Hwan Choe, MD, Kyung-Ja Cho, MD, Choon-Taek Lee, MD,
More informationUtility of 18 F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer
Utility of F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer Ngoc Ha Le 1*, Hong Son Mai 1, Van Nguyen Le 2, Quang Bieu Bui 2 1 Department
More informationP sumed to have early lung disease with a favorable
Survival After Resection of Stage I1 Non-Small Cell Lung Cancer Nael Martini, MD, Michael E. Burt, MD, PhD, Manjit S. Bains, MD, Patricia M. McCormack, MD, Valerie W. Rusch, MD, and Robert J. Ginsberg,
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationT cancer (NSCLC) has been the subject of a number of
Randomized Trial of Neoadjuvant Therapy for Lung Cancer: Interim Analysis Harvey I. Pass, MD, Helen W. Pogrebniak, MD, Seth M. Steinberg, PhD, James Mulshine, MD, and John Minna, MD Thoracic Oncology Section,
More informationPeri-Operative Chemo-Radio-Therapy Versus Radiotherapy Alone in NSC-Lung Cancer
Med. J. Cairo Univ., Vol. 82, No. 1, March: 7-11, 2014 www.medicaljournalofcairouniversity.net Peri-Operative Chemo-Radio-Therapy Versus Radiotherapy Alone in NSC-Lung Cancer HAMDY ELAYOUTY, M.D.*; EHAB
More informationThe role of adjuvant chemotherapy following resection of early stage thymoma
Perspective The role of adjuvant chemotherapy following resection of early stage thymoma Masatsugu Hamaji Department of Thoracic Surgery, Kyoto University Hospital, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto,
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated
More informationLONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL
LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL Stacey Su, MD; Walter J. Scott, MD; Mark S. Allen, MD; Gail E. Darling, MD; Paul A. Decker, MS; Robert
More informationRole of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City
Role of Surgery in Management of Non Small Cell Lung Cancer Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Introduction Surgical approach Principle and type of surgery
More informationStandard treatment for pulmonary metastasis of non-small
ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationSurgery for early stage NSCLC
1-3 March 2017, Manchester, UK Surgery for early stage NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France what
More informationPlattenepithelkarzinom des Ösophagus, 1 st -line
Plattenepithelkarzinom des Ösophagus, 1 st -line AIO-STO-0309 An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced
More informationBladder Preservation Protocols in the Treatment of Muscle-Invasive Bladder Cancer
Bladder-preserving therapy is a safe and effective alternative to cystectomy for carefully selected patients with bladder cancer. Michael Mahany. Trumpeter Swans on Byer s Lake. Photograph. Denali National
More informationValidation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer
Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department
More informationTreatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
More informationRadiation Therapy for Recurrent Esophageal Cancer after Surgery: Clinical Results and Prognostic Factors
Radiation Therapy for Recurrent Esophageal Cancer after Surgery: Clinical Results and Prognostic Factors Yoshiyuki Shioyama 1, Katsumasa Nakamura 1, Saiji Ohga 1, Satoshi Nomoto 1, Tomonari Sasaki 1, Toshihiro
More informationS non-small cell lung carcinoma (NSCLC), but the
Preoperative Chemotherapy and Irradiation for Stage I11 Non-Small Cell Lung Cancer L. Penfield Faber, MD, C. Frederick Kittle, MD, William H. Warren, MD, Philip D. Bonomi, MD, Samuel G. Taylor IV, MD,
More informationNSCLC: Staging & Prognosis. Neoadjuvant chemotherapy. Controversies in the management of early NSCLC: neoadjuvant vs adjuvant chemotherapy
Controversies in the management of early NSCLC: neoadjuvant vs adjuvant Sarita Dubey sst Professor, Medical ncology, UCSF NSCLC: Staging & Prognosis Pathologic Survival elapse (%) Stage 5 yr (%) Local
More informationResearch and Reviews Journal of Medical and Clinical Oncology
Comparison and Prognostic Analysis of Elective Nodal Irradiation Using Definitive Radiotherapy versus Chemoradiotherapy for Treatment of Esophageal Cancer Keita M 1,2, Zhang Xueyuan 1, Deng Wenzhao 1,
More informationPost-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer
Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer R. Taylor Ripley, Kei Suzuki, Kay See Tan, Manjit Bains,
More informationSalvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes
Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes Julie E. Bauman, MD, Michael S. Mulligan, MD, Renato G. Martins, MD, Brenda F.
More informationThere have been many attempts to develop effective
Postoperative Chemotherapy for Non-Small-Cell Lung Cancer* E. Carmack Holmes, M.D. The Lung Cancer Study Group has performed a number of postoperative adjuvant trials in patients with resectable DOD-small-ceO
More informationSurgical Treatment for Pulmonary Me. Tsunehisa; Kugimiya, Toshiyasu. Citation Acta medica Nagasakiensia. 1983, 28
NAOSITE: Nagasaki University's Ac Title Author(s) Surgical Treatment for Pulmonary Me Ayabe, Hiroyoshi; Tomita, Masao; Na Katsunobu; Nakao, Susumu; Eguchi, M Tsunehisa; Kugimiya, Toshiyasu Citation Acta
More informationNon-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital
Non-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital Muhammad Rizwan Khan,Sulaiman B. Hasan,Shahid A. Sami ( Department of Surgery, The Aga Khan University Hospital,
More informationTHE MAJORITY of patients with locally advanced lung
Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pn2 Non Small-Cell Lung Cancer: A Multicenter Phase II Trial Daniel
More informationMediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma*
Mediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma* Mediastinal Nodal Metastases in Lung Cancer Yoh Watanabe, M.D., F.C.C.P.; ]unzo Shimizu, M.D.; Makoto Tsubota, M.D.; and Takashi
More information肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 Outline Current status of radiation oncology in lung cancer Focused on stage III non-small cell lung cancer Radiation
More informationResearch Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy
SAGE-Hindawi Access to Research Lung Cancer International Volume 2011, Article ID 152125, 4 pages doi:10.4061/2011/152125 Research Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients:
More informationThe prognostic relevance of classifying neuroendocrine
Large Cell Neuroendocrine Carcinoma and Large Cell Carcinomas With Neuroendocrine Morphology of the Lung: Prognosis After Complete Resection and Systematic Nodal Dissection Joseph Zacharias, FRCS (CTh),
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationThe accurate assessment of lymph node involvement is
ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*
More informationMultifocal Lung Cancer
Multifocal Lung Cancer P. De Leyn, MD, PhD Department of Thoracic Surgery University Hospitals Leuven Belgium LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery Department of Pneumology Department
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationA phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008
A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 NCT02432365 Chyong-Huey Lai, MD On behalf of Principal investigator
More informationCase Scenario 1. The patient has now completed his neoadjuvant chemoradiation and has been cleared for surgery.
Case Scenario 1 July 10, 2010 A 67-year-old male with squamous cell carcinoma of the mid thoracic esophagus presents for surgical resection. The patient has completed preoperative chemoradiation. This
More informationPulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis
Survival in Synchronous vs Single Lung Cancer Upstaging Better Reflects Prognosis Marcel Th. M. van Rens, MD; Pieter Zanen, MD, PhD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD;
More informationA Proposed Strategy for Treatment of Superficial Carcinoma. in the Thoracic Esophagus Based on an Analysis. of Lymph Node Metastasis
Kitakanto Med J 2002 ; 52 : 189-193 189 A Proposed Strategy for Treatment of Superficial Carcinoma in the Thoracic Esophagus Based on an Analysis of Lymph Node Metastasis Susumu Kawate,' Susumu Ohwada,'
More informationMediastinal Lymph Node Dissection Improves Survival in Patients With Stages II and IIIa Non- Small Cell Lung Cancer
J. MAXWELL CHAMBERLAIN MEMORIAL PAPER Mediastinal Lymph Node Dissection Improves Survival in Patients With Stages II and IIIa Non- Small Cell Lung Cancer Steven M. Keller, MD, Sudeshna Adak, PhD, Henry
More information